ACTRN12612000465853尚未招募1 期
Safety and Immunogenicity of Sabin-IPV and adjuvanted Sabin-IPV in healthy adults
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 24 Years(—)
- 性别
- Male
入选标准
- •Subjects must fulfill all of the following criteria:
- •- University student attending the Faculty of Chemistry and Pharmacology, Camaguey University, Camaguey
- •- Age 18 to 24, inclusive at the time of enrollment
- •- In good health as determined by the outcome of medical history, physical examination screening/baseline labs, and clinical judgment of the investigator
- •- Must have received polio vaccinations with OPV according to the Cuban National Immunization Program as a child
- •- Preferred: number (and date) of polio vaccinations known
- •- Willingness and ability to adhere to the study regimen
- •- Having a signed informed consent form
排除标准
- •Temporary exclusion criteria for vaccination:
- •- If body temperature >=38C this will lead to postponement of participation and vaccination. Screening may continue when the temperature has normalized.
- •The exclusion criteria for vaccination are:
- •- IPV or OPV booster dose after the age of 12 years
- •- Known or suspected allergy against any of the vaccine components
- •- History of unusual or severe reactions to any previous vaccination
- •- Known or suspected disease or use of medication that may influence the immune system
- •- Known or suspected immune deficiency
- •- Systemic treatment with corticosteroids within one month before screening
- •- Administration of plasma (including immunoglobulins) or blood products three months prior to the study
- •- Blood donation within one month before screening
- •- Any vaccination within three months before screening and during the study until the last visit
- •- History of any neurological disorder including epilepsy or febrile seizures
- •- Evidence of excessive alcohol use or drug use
- •- Any infectious disease
- •- Participation in another clinical trial within three months before screening
- •- Abnormal pre-treatment laboratory parameters which are clinically relevant according to the investigator
- •The exclusion criteria for blood collections are:
- •- Bleeding disorders or the usage of anticoagulants
研究者
相似试验
已完成
1 期
Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy AdultsPoliomyelitisNCT01708720Pauline Verdijk45
尚未招募
4 期
Immune response to polio vaccine in malnourished and normally nourished Pakistani infantspolio vaccine immunogenecityInfection - Other infectious diseasesPublic Health - Other public healthACTRN12612000259842WHO840
已完成
不适用
Brazilian pentavalent vaccineISRCTN95974322Bio-Manguinhos/Fiocruz (Brazil)1,200
未知
3 期
Immunogenicity and Safety of the DTaP-IPV (sanofi Pasteur Kitasato) Combined Vaccine (DD-687) given subcutaneously as a three-dose primary and booster vaccination versus commercially available DTaP (Kitasato) and Oral Polio Virus (OPV) Vaccines in Infants in JapaProphylaxis of pertussis, diphtheria, tetanus, and poliomyelitis infection.JPRN-jRCT2080221313DAIICHISANKYO Co.,Ltd., Sanofi Aventis KK374
尚未招募
Unknown
evel of immunity and safety of two types of vaccines administered for the prevention ofJapanese encephalitis in an interchangeable dosing schedule among healthy Indian children: Amulti-centric studyCTRI/2023/07/055155Indian Council of Medical Research
